Argenx vs Neurocrine Biosciences
Argenx is the larger business, with $4.15bn of revenue in fiscal 2025 against $2.86bn for Neurocrine Biosciences (1.5 times as much). Argenx grew faster (89.9% against 21.4%). Argenx kept more of each dollar of sales as profit: a net margin of 31.1% against 16.7%. Argenx carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | ArgenxARGX, 2025 | Neurocrine BiosciencesNBIX, 2025 |
|---|---|---|
| Revenue | $4.15bn | $2.86bn |
| Revenue growth | 89.9% | 21.4% |
| Net income | $1.29bn | $479m |
| Operating margin | 25.4% | 21.6% |
| Net margin | 31.1% | 16.7% |
| Return on equity | 20.2% | 16.4% |
| Free cash flow | $679m | $749m |
| Cash | $3.49bn | $713m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $168m |
| Employees | — | 1,800 |
| Market value | $55.65bn | $16.93bn |
| Price vs our value range | — | Below our value range |
| Moat score | — | 61 (Moderate) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 40 sales |